AtaiBeckley (ATAI) Non Operating Investment Income (2025)
AtaiBeckley (ATAI) posted Non Operating Investment Income of $16.9 million for Q2 2021.
Powered by 
Analysis
AtaiBeckley (ATAI) Non Operating Investment Income (2025) Analysis & Trends
AtaiBeckley has reported Non Operating Investment Income for 1 years, with the latest figure at $16.9 million in Q2 2021.
- Quarterly Non Operating Investment Income changed N/A year-over-year to $16.9 million in Q2 2021, while the trailing twelve-month figure through Jun 2022 was $16.9 million (changed N/A YoY) and the FY2021 annual result came in at $16.9 million, changed N/A from the prior year.
- Non Operating Investment Income steadied at $16.9 million in Q2 2021 per ATAI's latest filing.
- Over five years, Non Operating Investment Income peaked at $16.9 million in Q2 2021 and troughed at $16.9 million in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | AtaiBeckley | 1.60 Bn | 1.60 Bn | - | - |